MedTrace Logo

This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component in Healthy Adult Volunteers in Fed Condition.

NCT05823883 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-05-26

No results posted yet for this study

Summary

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6014 and each component in healthy adult volunteers in fed condition.

Conditions

  • DW6014

Interventions

DRUG

DW6014

Drug: DW6014 Single oral administration of DW6014 in fed condition Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition

Sponsors & Collaborators

  • Dong Wha Pharmaceutical Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2023-07-31
Completion
2023-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05823883 on ClinicalTrials.gov